
Rachna Shroff, MD, MS, FASCO
@rachnatshroff
Followers
5K
Following
14K
Media
618
Statuses
4K
GI Oncologist, focus pancreatic, biliary cancers, personalized tx’s. Love to dance, travel, and spend time with my family. ASCO FCOI: https://t.co/oXHqwATEeE
University of Arizona
Joined October 2012
Thank you @HodaAndJenna for raising awareness for #PancreaticCancer - was a privilege to demystify this disease! Plus, since @mindykaling was featured too, I feel like we are now buddies #desisisters! @UAZCancer @UAZHealth @UAWomenAcadMed @HemOncWomenDocs
today.com
Nurses Mike and Missy Skaggs share their battle against pancreatic cancer after Mike was diagnosed with the disease at 47. Mike’s doctor, Dr. Christopher Sonnenday, also discusses the difficulty with...
5
10
81
RT @AnaVManana: 🚨 Leadership isn’t built alone! .Join us in Arizona for #LEAD2025 — a unique space to recharge, connect, and grow as leader….
0
15
0
RT @doctorpemm: 👉👉👉Lovely to have the cherished opportunity to give a toast 🥂 along with @rachnatshroff to an all-time amazing couple .@ni….
0
4
0
There are some moments that need no caption…@ninashah33 and @DoctorGRao brought the #getRAOdy all weekend!
6
1
42
RT @Latinamd: Look at you tonight! . Lovely to celebrate the beautiful bride (myeloma queen) @ninashah33 and participate in my first ever….
0
1
0
RT @OncLive: Shubham Pant, MD, MBBS and @rachnatshroff highlight how recent breakthroughs in KRAS-specific inhibitors—such as those targeti….
0
7
0
RT @oncodaily: 25 Posts Not To Miss From ESMO GI 2025. @myESMO @amalsargsyan @MyriamChalabi @rachnatshroff @Erman_Akkus @CathyEngMD @Macaru….
0
7
0
RT @NazliDizman: 🙋♀️Hello!! How's your schedule this fall? .🌟#WomenInOncology, save Sep 27-28 for #LEAD25!.It's a fantastic opportunity fo….
0
17
0
RT @DrShubhamPant: And that’s a wrap on #ESMOGI in vibrant Barcelona! Honored to chair the #KRAS in pancreatic cancer symposium, present th….
0
2
0
#ESMOGI25 orals: CM 9DW QOL in #HCC .@myESMO #ESMOAmbassadors.- Nivo/Ipi with ⬇️ HrQOL deterioration .- PROs show less bother from side effects with Nivo/Ipi.- No negative impact of TRAE related 🛑 on efficacy
0
5
16
#ESMOGI25 orals: TALENTACE, TACE plus Atezo/Bev in intermediate to high tumor burden #HCC.- ⬆️ TACE-PFS 11.3 vs 7 mths.- ORR 49 vs 34%.- OS immature .#ESMOAmbassadors @myESMO
0
3
11
#ESMOGI25 orals: CM 8HW QOL.- Nivo/Ipi in MSI-H/dMMR #CRC.- No ⬇️ in HrQOL .- Given known potential tox, reassuring data.@myESMO #ESMOAmbassadors
0
1
10
#ESMOGI25 orals: PANOVA-3 QOL is out ‼️ @MacarullaTeresa .- ⬆️ global QOL.- ⬇️ time to deterioration for pain.- ⬇️ opioid use .TTF needing to be worn 18 hrs/day ⁉️ @myESMO #ESMOAmbassadors
0
1
9
#ESMOGI25 orals: MATTERHORN PROs are here 👏:.- PRO compliance rate high ✅.- No decline in QOL with FLOT + D .- Anxiety 📉 after therapy .#ESMOAmbassadors @myESMO @salahAlBatran
0
11
19
Beyond PDL1 for #HCC - great overview by Dr. Stephen Chan. 🔑 takeaways:.- Multiple novel 🎯 .- cell therapies coming 🥳.- T cell engagers 🧐 .#ESMOGI25 #ESMOAmbassadors @myESMO
1
0
9
Excellent summary for intermediate stage #HCC by @GIcancerDoc! Progress but many ❓🤨:.- Is PFS the right endpoint?.- TACE vs TARE.- Sequence vs concurrent.#ESMOGI25 #ESMOAmbassadors @myESMO
1
10
31